Table_1_COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis.doc
Background: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are two major infectious diseases posing significant public health threats, and their coinfection (aptly abbreviated COVID-TB) makes the situation worse. This study aimed to investigate the clinical features and prognosis of COVID-TB cases.
Methods: The PubMed, Embase, Cochrane, CNKI, and Wanfang databases were searched for relevant studies published through December 18, 2020. An overview of COVID-TB case reports/case series was prepared that described their clinical characteristics and differences between survivors and deceased patients. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) for death or severe COVID-19 were calculated. The quality of outcomes was assessed using GRADEpro.
Results: Thirty-six studies were included. Of 89 COVID-TB patients, 19 (23.46%) died, and 72 (80.90%) were male. The median age of non-survivors (53.95 ± 19.78 years) was greater than that of survivors (37.76 ± 15.54 years) (p < 0.001). Non-survivors were more likely to have hypertension (47.06 vs. 17.95%) or symptoms of dyspnea (72.73% vs. 30%) or bilateral lesions (73.68 vs. 47.14%), infiltrates (57.89 vs. 24.29%), tree in bud (10.53% vs. 0%), or a higher leucocyte count (12.9 [10.5–16.73] vs. 8.015 [4.8–8.97] × 109/L) than survivors (p < 0.05). In terms of treatment, 88.52% received anti-TB therapy, 50.82% received antibiotics, 22.95% received antiviral therapy, 26.23% received hydroxychloroquine, and 11.48% received corticosteroids. The pooled ORs of death or severe disease in the COVID-TB group and the non-TB group were 2.21 (95% CI: 1.80, 2.70) and 2.77 (95% CI: 1.33, 5.74) (P < 0.01), respectively.
Conclusion: In summary, there appear to be some predictors of worse prognosis among COVID-TB cases. A moderate level of evidence suggests that COVID-TB patients are more likely to suffer severe disease or death than COVID-19 patients. Finally, routine screening for TB may be recommended among suspected or confirmed cases of COVID-19 in countries with high TB burden.
History
References
- https://doi.org//10.1038/s41581-020-00357-4
- https://doi.org//10.3389/fimmu.2020.01991
- https://doi.org//10.1093/cid/ciaa530
- https://doi.org//10.1007/s11427-020-1668-5
- https://doi.org//10.1183/13993003.02328-2020
- https://doi.org//10.32592/ircmj.2020.22.10.196
- https://doi.org//10.12659/AJCR.927628
- https://doi.org//10.1136/bmjebm-2017-110853
- https://doi.org//10.1016/S1470-2045%2820%2930309-0
- https://doi.org//10.1136/bmj.327.7414.557
- https://doi.org//10.12659/AJCR.926034
- https://doi.org//10.1016/j.idcr.2020.e00973
- https://doi.org//10.3201/eid2611.201536
- https://doi.org//10.4269/ajtmh.20-0851
- https://doi.org//10.3201/eid2611.202752
- https://doi.org//10.1183/13993003.01708-2020
- https://doi.org//10.1183/13993003.03408-2020
- https://doi.org//10.4269/ajtmh.20-0756
- https://doi.org//10.21203/rs.3.rs-59744/v1
- https://doi.org//10.1186/s12890-020-01285-6
- https://doi.org//10.5588/ijtld.20.0163
- https://doi.org//10.1002/jmv.25943
- https://doi.org//10.1002/ppul.24927
- https://doi.org//10.1016/j.chest.2020.08.724
- https://doi.org//10.4269/ajtmh.20-0737
- https://doi.org//10.1186/s12887-020-02308-1
- https://doi.org//10.1016/j.rmcr.2020.101146
- https://doi.org//10.1136/bcr-2020-238597
- https://doi.org//10.1016/j.transci.2020.102821
- https://doi.org//10.16718/j.1009-7708.2020.05.017
- https://doi.org//10.1016/j.jinf.2020.06.062
- https://doi.org//10.1016/j.pulmoe.2020.05.002
- https://doi.org//10.11604/pamj.2020.36.374.24260
- https://doi.org//10.5005/jp-journals-10071-23662
- https://doi.org//10.1093/cid/ciaa1198
- https://doi.org//10.1186/s13613-020-00706-3
- https://doi.org//10.1093/gerona/glaa089
- https://doi.org//10.1183/13993003.00524-2020
- https://doi.org//10.1016/j.jaci.2020.04.006
- https://doi.org//10.3969/j.issn.1673-8640.2020.06.008
- https://doi.org//10.16016/j.1000-5404.202002097
- https://doi.org//10.3760/cma.j.cn112338-20200318-00378
- https://doi.org//10.3760/cma.j.cn121430-20200301-00153
- https://doi.org//10.1101/2020.03.10.20033795
- https://doi.org//10.1093/gerona/glaa094
- https://doi.org//10.1016/S0140-6736%2820%2930566-3
- https://doi.org//10.1016/S1473-3099%2820%2930243-7
- https://doi.org//10.3947/ic.2020.52.2.154
- https://doi.org//10.1183/13993003.01227-2020
- https://doi.org//10.1016/j.ijid.2020.03.017
- https://doi.org//10.1016/j.jinf.2020.04.021
- https://doi.org//10.1042/CS20201268
- https://doi.org//10.1136/thoraxjnl-2020-215322
- https://doi.org//10.1001/jamacardio.2020.1017
- https://doi.org//10.1007/s11886-020-01291-4
- https://doi.org//10.1056/NEJMoa2002032
- https://doi.org//10.2214/AJR.20.22976
- https://doi.org//10.1016/j.jaut.2020.102473
- https://doi.org//10.26355/eurrev_202011_23631
- https://doi.org//10.1016/j.thromres.2020.05.006
- https://doi.org//10.1056/NEJMc2022236
- https://doi.org//10.1186/s13054-020-03400-9
- https://doi.org//10.5588/ijtld.15.0031
- https://doi.org//10.3201/eid2611.202602
- https://doi.org//10.1016/S2214-109X%2820%2930288-6
- https://doi.org//10.1016/S2214-109X%2820%2930428-9
Usage metrics
Read the peer-reviewed publication
Categories
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Primary Health Care
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Medical Genetics (excl. Cancer Genetics)
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care